Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Celldex Therapeutics, Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zoetis (ZTS) and Celldex (CLDX). Zoetis (ZTS) In a report release...

Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS) and Celldex (CLDX)

In a report released today, Richard Law CFA from Goldman Sachs maintained a Hold rating on Celldex, with a price target of $38.00. According to Tip...

Goldman Sachs Reaffirms Their Hold Rating on Celldex (CLDX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Celldex (CLDX) with bullish sent...

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vanda (VNDA) and Celldex (CLDX) with bullish sentime...

Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Celldex (CLDX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN), Celldex (CLDX) and Nurix Therapeut...

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Celldex (CLDX) and Nurix Therapeutics (NRIX)

Wells Fargo analyst Derek Archila maintained a Buy rating on Celldex yesterday and set a price target of $48.00. The company’s shares closed yester...

Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Helus Pharma (HELP) and Celldex (CLDX) with bullish ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CLDX	$41.95	0.00%	670.93K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CLDX	$41.95	0%	670.93K
3
4
5
6

CLDX

Get Celldex Therapeutics, Inc. Data in Excel

Get Celldex Therapeutics, Inc. Data in Excel